-
Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes. Investment and JV FormationThe joint…
-
China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products
•
The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement (VBP) tender, focusing on artificial lenses and sports medicine medical consumables, with an encouragement for products utilizing additive manufacturing technology, namely 3D printing, to participate. Scope of the TenderThe tender’s scope encompasses a range of…
-
Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU
•
China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received CE IVDR certifications in the European Union for two of its fully automatic chemiluminescence immunoassay analyzer products. This regulatory milestone marks a significant step forward for the company in expanding its presence in the EU…
-
Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership agreement with Chongqing Yuyan Pharmaceutical Co., Ltd. This strategic alliance involves a significant investment and the acquisition of exclusive commercialization rights for Yuyan’s medical aesthetics product in key regions. Investment and Stake AcquisitionAs per the…
-
Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China
•
Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into a partnership with China’s Healthcare Cloud, an online health services provider, during the recent China International Import Expo (CIIE) meeting. The collaboration aims to enhance ophthalmic services in China by leveraging the strengths of both…
-
Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY) donanemab is set to receive priority review status for the treatment of early-stage Alzheimer’s disease (AD). This development is significant as it pertains to the drug’s potential use in patients with mild cognitive impairment or…
-
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
•
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter of 2023. The company reported a 13.5% decrease in sales, amounting to USD 8.8 million. Despite this downturn, several positive developments indicate a promising outlook for the company in the near future. Revenue Generator and…
-
Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal
•
China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric antigen receptor (CAR) T cell therapies with Novartis Pharma AG (NYSE: NVS) in a landmark USD 1.1 billion deal. The Swiss pharmaceutical giant has acquired exclusive global development, manufacturing, and commercialization rights to certain assets…
